Trial Profile
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Carboplatin; Doxorubicin; Paclitaxel; Topotecan
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer; Uterine cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Advenchen Laboratories
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2021 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 08 Oct 2021 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.